Arvinas vs Vir Biotechnology
Arvinas is the larger business, with $263m of revenue in fiscal 2025 against $68.6m for Vir Biotechnology (3.8 times as much). Arvinas grew faster (-0.3% against -7.6%). Arvinas kept more of each dollar of sales as profit: a net margin of -30.8% against -638.9%. Vir Biotechnology carries less debt relative to equity (0.0% against 0.1%).
| Latest fiscal year | ArvinasARVN, 2025 | Vir BiotechnologyVIR, 2025 |
|---|---|---|
| Revenue | $263m | $68.6m |
| Revenue growth | -0.3% | -7.6% |
| Net income | −$80.8m | −$438m |
| Operating margin | -45.1% | -699.2% |
| Net margin | -30.8% | -638.9% |
| Return on equity | -16.2% | -45.7% |
| Free cash flow | −$276m | −$397m |
| Cash | $143m | $232m |
| Total debt | $600,000 | $0 |
| Debt to equity | 0.1% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $91.9m | — |
| Employees | 246 | 367 |
| Market value | $462m | $1.91bn |
| Price vs our value range | — | — |
| Moat score | 9 (Weak) | 27 (Weak) |
| Insider trades, 12 months | 1 buys, 23 sales | 0 buys, 35 sales |